Heart Failure Hospitalization

Implicity announced it received 510(k) clearance from the FDA for its new AI algorithm to assess risk for future HF events from data gathered from various cardiac implantable electronic devices.

ATLANTA — In the EMPACT-MI trial, empagliflozin treatment soon after an acute MI did not significantly lower risk for HF hospitalization or death from any cause compared with placebo among patients with increased risk for HF.

ATLANTA — Transcatheter implant of an inter-atrial shunt had drastically different results depending on ejection fraction in patients with HF, a speaker reported at the American College of Cardiology Scientific Session.

A short-stay strategy designed to lower cost of care may improve quality of life of low-risk patients with acute HF in the ED, but the trial was underpowered due to low enrollment during the COVID-19 pandemic, researchers reported.

SAN FRANCISCO — Data show a novel transcatheter mitral valve edge-to-edge repair system was associated with a sustained reduction in mitral regurgitation plus functional and quality-of-life gains for patients at prohibitive surgical risk.

SAN FRANCISCO — A fourth-generation mitral valve transcatheter edge-to-edge repair system was associated with durable reduction in mitral regurgitation severity to mild or less for most patients, including those with complex anatomy.

Moderately symptomatic patients with HF with elevated peptides or prior HF hospitalization, while experiencing differing outcome trajectories, derived similar benefit from hemodynamic-guided management, a speaker reported.

Adults with HF who reported living alone were more likely to be hospitalized for any reason compared with those who reported living with others, according to data from a meta-analysis.

Complete revascularization was associated with reduced HF hospitalization and both CV and all-cause death among patients presenting with ACS and multivessel CAD, researchers reported in the Journal of the American Heart Association.

Beta-blockers may reduce risk for death or hospitalization for people with HF with preserved ejection fraction more effectively than calcium channel blockers, according to data from a meta-analysis of randomized controlled trials.